Drug discovery

#Blood cancer #Cancer research #Drug discovery

Advances and challenges in blood cancer drug discovery

Drug Discovery World speaks to companies at the cutting edge of innovation in blood cancer therapeutics.  The prognosis for patients with blood cancers has improved dramatically since the turn of the century. Thanks to an ever-growing array of treatments becoming available, there has been significant progress in treating B cell leukaemias like acute lymphoblastic leukaemia (B-ALL), as well… Read More

#Cancer Research #Exclusive Content

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Large-scale proteomics enables early detection and disease interception

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Clinical trial #Drug discovery #Milner Therapeutics Institute #UK

The role of universities and industry in driving translation of therapeutics

Professor Cathy Tralau-Stewart PhD, Executive Director, Milner Therapeutics Institute, University of Cambridge, UK, asks why a new approach is needed in the UK for getting therapies to the market. Evolution of the translational path   Academic institutions contribute a substantial share of the therapeutic approaches that ultimately reach patients (1), but the path to translating such innovation to… Read More

#Exclusive Content

#Artificial intelligence (AI) #Drug discovery #Investment #Machine learning

Pharmacelera raises $6m to advance AI drug discovery  

Deep tech company Pharmacelera has raised $6 million in an investment round to help accelerate its expansion in the United States and grow its platform.   Pharmacelera uses its proprietary quantum mechanics and artificial intelligence (QaiM) algorithms to find novel and diverse molecular candidates across the chemical “exaSpace”.   The company says its algorithms can generate… Read More

#News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Is trajectory-based profiling the next frontier in precision medicine?

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#AI #Drug discovery #Women's health

Partnership to develop treatments for gynaecological diseases 

Tejin Pharma has partnered with pharmaceutical company Aska Pharmaceutical to develop treatments for gynaecological diseases.  As per the agreement, the companies will collaborate to accelerate the early-stage drug discovery process aimed at identifying innovative therapeutic candidates.   The companies intend to develop novel small-molecule drug candidates, a process which… Read More

#News

#Cell and gene therapy #Crown Bioscience #Drug discovery #Gene editing #Preclinical development

How next-gen preclinical models can transform cell and gene therapies

David Vallerand, Director of Scientific Engagement for Crown Bioscience, examines the technologies advancing cell and gene therapy drug discovery.   Transforming CGT development through next-generation preclinical models   Introduction Cell and gene therapy (CGT) is transforming the field of oncology. Unlike traditional cytotoxic treatments, CGT leverages the body’s immune system and targets the genetic drivers of cancer to… Read More

#Exclusive Content

#Drug discovery #John Hopkins University #Syngene

Syngene and John Hopkins University to advance drug discovery  

Syngene International has announced a strategic collaboration with John Hopkins University to advance early-stage drug discovery programmes.  The collaboration will incorporate Syngene’s SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development.   Syngene also intends to use its… Read More

#Business & Investment #News

Parkinson's disease
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Parkinson’s biomarkers detected 12 years pre-symptomatically

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Assays #Drug discovery #Oncology #Revvity #SLAS2026 #SPT Labtech

SLAS2026: Day One Round-Up  

DDW covers some of the biggest announcements from the first day of SLAS2026.     Carterra launches high-throughput SPR instrument   High-throughput technology provider Carterra  launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the… Read More

#News

#Drug discovery #High throughput screening #Revvity #SLAS2026

Revvity launches high-impact discovery platform 

Revvity launched multiple new discovery platforms and technologies at SLAS2026, all designed to accelerate high-throughput drug discovery workflows.   The company debuted its Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation.   The Opera Phenix OptIQ high-content screening system is designed to reduce bottlenecks in phenotypic screening and… Read More

#News

Cannabinoid research
#Assays #BMG Labtech #Cannabinoid #Drug discovery

The study of cannabinoid-based drugs: developments and opportunities

This paid-for advertorial by BMG Labtech appeared in DDW Volume 27 – Issue 1, Winter 2025/2026.   Scientists are exploring new strategies to advance drug discovery and development related to cannabinoid research due to significant unmet needs in different therapeutic areas. Microplate-based interaction assays show promise for the study of a wide range of cannabinoid signalling events. Developments in cannabinoid research continue to gather… Read More

#Exclusive Content

#Drug discovery #SLAS2026

From insight to impact: Catalyzing discovery at SLAS2026

By Jill Hronek, SLAS Director of Marketing and Communications.   Drug discovery is rarely the result of a single breakthrough. It is almost always catalyzed — by the convergence of disciplines, by the adoption of new technologies, and by connections between people who approach problems from different perspectives. That idea sits at the… Read More

#Exclusive Content

Researcher in a medical lab
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Predict disease risk long before diagnosis

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#AI #Drug discovery #United States

From the Editor: A year in turmoil

For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty.   The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position where it attempted to dictate… Read More

#Exclusive Content #Opinion